Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Michael Stillabower

Cardiovascular Disease Newark, DE Medical Doctor

NPI 1548237472 CMS profile 205473

252 Chapman Rd, Suite 150, Newark, DE 19702

Open in the dashboard

General payments

$3,833

95 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$23,994 paid to institutions, not to them · program year 2019

Through program year 2022, Michael Stillabower of Newark, DE is reported in the CMS Open Payments database as having received $3,833 across 95 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $23,994 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 63rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $18 1
2021 General $15 1
2020 General $179 11
2019 General $3,621 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Stillabower
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Michael Stillabower were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Michael Stillabower Cardiovascular Disease median Middle half National median
2019 $3,621 $450 $127–$1,392 $163
2020 $179 $242 $77–$751 $114
2021 $15 $335 $101–$1,037 $132
2022 $18 $395 $121–$1,211 $149
2023 $0 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Merit Medical Systems Inc $2,357 12 payments
  2. AstraZeneca Pharmaceuticals LP $382 19 payments
  3. Amgen Inc. $211 13 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $144 8 payments
  5. Amarin Pharma Inc. $123 8 payments
  6. Sanofi-Aventis U.S. LLC $113 7 payments
  7. Novartis Pharmaceuticals Corporation $109 7 payments
  8. Janssen Pharmaceuticals, Inc $107 7 payments
  9. Preventice Services, LLC $99 1 payment
  10. Regeneron Healthcare Solutions, Inc. $39 3 payments
  11. Other $150 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Travel and Lodging $2,265 11 payments
  2. Food and Beverage $1,568 84 payments
Products named General payments · program years 2019–2022
  1. BRILINTA $382 19 payments
  2. Repatha $211 13 payments
  3. Corlanor $211 13 payments
  4. JARDIANCE $144 8 payments
  5. PRALUENT Cardiovascular $113 7 payments
  6. Vascepa $109 7 payments
  7. ENTRESTO $109 7 payments
  8. XARELTO $107 7 payments
  9. PRADAXA $73 5 payments
  10. PRALUENT Cardiovascular And Metabolism $39 3 payments
  11. Other $178 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

95 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record